TGF-β has been shown by others to upregulate LOX in prostate and breast tumor cells [36, 44] and aggressive prostate cancer cells expresses more TGF-β than indolent tumors and high TGF-β expression in tumor epithelial cells is associated with a poor outcome in our cohort of prostate cancer patients [45]. Here, LOX is linked to prostate carcinoma.